Skip to NavigationSkip to content

UCB to invest £1 billion into UK R&D

Published on 06/12/18 at 11:41am

The Brussels-based multinational UCB will invest £1 billion into UK research and development, according to the government’s Life Sciences Sector Deal, which details public and private sector investments into Britain’s life sciences industry.

Meanwhile £75 million will be invested into the development of new AI driven diagnostic tests while £50 million will be invested in digital pathology programmes and £37.5 million into regional Digital Innovation Hubs.

Business secretary Greg Clark commented: “This is our modern Industrial Strategy in action as we work hand in hand with industry to ensure the UK remains the go-to destination for launching new businesses, new discoveries and treatments to benefit health around the world.”

UCB’s investment will be focused on a new £150-200 million purpose built research facility that will support 650 high-skilled jobs.

“At UCB, we are proud of our heritage in the UK and I am very pleased to announce our planned investment to support the construction of a major R&D hub in the UK, which will enable us to build upon our numerous active collaborations with UK universities, biotechs and medical research charities and continue our successful track record of bringing innovative medicines discovered in the UK to patients globally,” said Jean-Christophe Tellier, UCB’s chief executive.

Louis Goss

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches